These data indicate that GTCpFE, but not ASA (Fig. 4d), is capable of inhibiting NFκB activity in breast cancer cells, by blocking IKKα/β phosphorylation and subsequent activation of the p65 transcription factor. Here, RELA is linked to breast carcinoma.